No Detail Found!

Comparison of Intracoronary Verapamil and Adenosine for No-Reflow in Normotensive Patients with Acute Coronary Syndrome: A Prospective Observational Study

Author(s)
Qazi Najeeb Ullah Amin Hayatabad Medical Complex,Peshawar,Pakistan
Muhammad Abdur Rauf Kuwait Teaching Hospital Peshawar,,Pakistan
Syed Hashim Ali Shah Hayatabad Medical Complex,Peshawar,Pakistan
Sami Ullah Shakir National Institute of Cardiovascular Diseases, Karachi, Pakistan
Syed Kashif Ullah Shah Hayatabad Medical Complex,Peshawar,Pakistan
Arshad Ali National Institute of Cardiovascular Diseases, Karachi, Pakistan
Nasir Ali Hayatabad Medical Complex,Peshawar,Pakistan
Abstract
Objectives: This study aimed to compare the efficacy of intracoronary verapamil versus adenosine in managing the no-reflow phenomenon in normotensive patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Methodology: We conducted a prospective observational study at Hayatabad Medical Complex Peshawar from March 2023 to March 2024. A total of 150 normotensive ACS patients scheduled for PCI were enrolled and treated with either intracoronary verapamil (200 µg) or adenosine (48 µg) based on the clinical judgment of the treating cardiologist upon identifying the no-reflow phenomenon. The primary outcomes included improvements in myocardial perfusion, assessed by the achievement of TIMI III flow immediately and at 30 minutes via angiographic analysis. Secondary outcomes assessed were microvascular resistance (IMR), endothelial function (FMD), and the incidence of major adverse cardiac events (MACE) within six months. Results: The verapamil group exhibited a higher percentage of patients achieving TIMI III flow post-treatment compared to the adenosine group (92% vs. 78%, p = 0.03). Both treatment groups demonstrated reductions in IMR (verapamil: 18.5 ± 2.8 units; adenosine: 19.1 ± 3.1 units, p = 0.29) and improvements in FMD (verapamil: 4.1 ± 0.5%; adenosine: 3.9 ± 0.6%, p = 0.15). The incidence of MACE was 18% in the verapamil group and 8% in the adenosine group, indicating comparable safety profiles for both agents. Conclusion: Intracoronary verapamil and adenosine both effectively enhance myocardial perfusion and endothelial function in normotensive ACS patients following PCI. Verapamil showed a slight advantage in achieving TIMI III flow and reducing microvascular resistance, suggesting it may offer superior benefits in specific clinical scenarios. These results support the use of both agents in managing the no-reflow phenomenon, with potential preference for verapamil in particular contexts.
Publication Details
Page(s) 343-348
Published Journal: Pakistan Heart Journal, Volume: 57, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
Percutaneous Coronary Intervention (PCI), Acute Coronary Syndrome (ACS), No-Reflow Phenomenon, Intracoronary verapamil
References
Çelik İE,Öztürk S,Yarlıoğlu M,Barutçu O,Akgün O,Duran M .2023 .The Association Between Atherogenic Index of Plasma and NoReflow Phenomenon in Acute Coronary Syndrome. Anatol J Cardiol, 27(12) : 712-9.
.2013 .(6):CD009503.. , : .
.2022 .Comparison of Intracoronary Epinephrine and Adenosine for NoReflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial). Circ Cardiovasc Interv, 15(2) : e011408.
Saood Y,Salman A,Khan M,Asim M. Comparison M .2023 .Of Intracoronary Epinephrine To Standard Treatments Alone For Refractory Coronary No-Reflow In STEMI Patients Undergoing Primary Percutaneous Coronary Intervention. Biol Clin Sci Res J, : 277.
Saif M,Amin MU,Khan HS,Maken GR,Aziz Z,Janjua AF .2020 .Comparison of intracoronary verapamil vs adenosine for restoration of coronary blood flow post percutaneous coronary intervention (PCI) in patients with no-reflow. Pak Arm Forces Med, 70(Suppl-4) : S833-37.
Nguyen LH,Drew DA,Graham MS,Joshi AD,Guo CG,Ma W .2020 .Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health, 5(9) : e475-83.
Kiani SS,Nadeem A,Chauhdry AA,Farahe A,Shafique HM,Ashraf W .2022 .Treatment of Refractory No-Reflow in Cardiac Catheterization Laboratory; Role of Intracoronary Verapamil (A Case Report). Pak Arm Forces Med, 72 : S543-6.
0

Citations

0

Downloads

109

Views